Target intelligence / Profile preview

Gastric mucosal proteins and enzymes

Molecular classification
Enzyme, Transporter, Structural protein, Receptor
01

Overview

Gastric mucosal proteins and enzymes represent a heterogeneous group of molecular entities within the stomach lining that are vital for digestion and epithelial defense. This category includes the H+/K+ ATPase (proton pump), which mediates the final step of acid secretion, and enzymes such as pepsinogen and gastric lipase that initiate the breakdown of dietary proteins and fats (StatPearls, 2023). Additionally, structural proteins like mucins (MUC5AC, MUC6) and trefoil factors are essential for maintaining the gastric mucus-bicarbonate barrier, which protects the mucosa from the corrosive effects of luminal acid and proteases (NCBI, 2022). These proteins serve as primary targets for pharmacological intervention; for instance, proton pump inhibitors (PPIs) covalently bind to the H+/K+ ATPase to treat acid-peptic disorders, while cytoprotective agents like sucralfate interact with exposed mucosal proteins to form a physical shield over ulcerated tissue (StatPearls, 2023). Understanding the function and regulation of these proteins is crucial for managing gastrointestinal conditions such as peptic ulcer disease, GERD, and chronic gastritis.

Other names
Gastric mucosal factorsStomach enzymes and proteinsGastric secretory proteinsGastric mucosal barrier components
02

Mechanism of action

The primary mechanisms of action for drugs targeting these proteins include the irreversible inhibition of the gastric H+/K+ ATPase (proton pump) to suppress hydrochloric acid secretion (StatPearls, 2023); the formation of a protective physical barrier by binding to mucosal proteins like albumin and fibrinogen at ulcer sites (NIH, 2022); and the stimulation of protective factors such as mucus and bicarbonate secretion (PubMed, 2021).

03

Biological functions

DigestionAcid-base homeostasisMucosal protectionProteolysis
04

Disease associations

Peptic ulcer diseaseGastroesophageal reflux disease (GERD)GastritisGastric cancerZollinger-Ellison syndrome
05

Safety considerations

HypergastrinemiaVitamin B12 deficiencyHypomagnesemiaIncreased risk of Clostridioides difficile infectionGastric mucosal atrophy
06

Interacting drugs

Omeprazole

8 more in the full profile.

07

Biomarkers

Pepsinogen I (PGI)Pepsinogen II (PGII)PGI/PGII ratioSerum gastrin

Beyond the preview

Go deeper on Gastric mucosal proteins and enzymes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric mucosal proteins and enzymes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call